Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host.
In this webinar, we have invited Dr. Yanfeng Li from GenScript Biotech Corporation to discuss about challenges in COVID-19 management; post vaccination NAb evaluation & protection versus new variants; and limitations of existing serology methods.
We will also review cPassTM clinical performance, NAb longevity in infected & vaccinated individuals, and why cPassTM can potentially serve as COVID-19 ‘exit strategy’ to reopen the economy and society.
About GenScript Biotech Corporation: global leading biotech company with gene synthesis, protein, antibody and preclinical drug development service capabilities.
About cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit: cPass™ kit allows rapid detection of total neutralizing antibodies (NAbs) in a sample. NAbs are functional antibodies that specifically block the interaction between virus and host cell and therefore prevent the viral entry into the host cell. The cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit was co-developed by Duke-NUS Medical School (Duke-NUS), GenScript, and DxD Hub.